AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31684886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management and exercise interventions
Number of subjects: 149
Study 31684886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 149
Study 31684886 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 149
Study 31684919 — intervention group
Group type: EXPERIMENTAL
Intervention: Precarious patients
Number of subjects: 0
Study 31684919 — intervention group
Group type: COMPARATOR
Intervention: Non-precarious patients
Number of subjects: 0
Study 31684919 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary analysis
Number of subjects: 0
Study 31684919 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical information systems method
Number of subjects: 0
Study 31684919 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropological analysis
Number of subjects: 0
Study 31684919 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis
Number of subjects: 0
Study 31684927 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (400 mg in enhanced absorption formulation)
Number of subjects: 8
Study 31684927 — intervention group
Group type: COMPARATOR
Intervention: Non-hydrolyzed plasma samples
Number of subjects: 8
Study 31684993 — intervention group
Group type: EXPERIMENTAL
Intervention: LINAC VMAT (AAA)
Number of subjects: 10
Study 31684993 — intervention group
Group type: EXPERIMENTAL
Intervention: LINAC VMAT (AXB)
Number of subjects: 10
Study 31684993 — intervention group
Group type: COMPARATOR
Intervention: Cyberknife
Number of subjects: 10
Study 31685074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol testing
Number of subjects: 294
Study 31685074 — intervention group
Group type: COMPARATOR
Intervention: Placebo testing
Number of subjects: 294
Study 31685415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 19
Study 31685415 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 19
Study 31685467 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI) of cefepime, median duration of 4.5 days, targeting a blood concentration of 16 mg/liter
Number of subjects: 21
Study 31685467 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for cefepime (not specified in detail)
Number of subjects: 21
Study 31685468 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin; specific dosage and duration not mentioned
Number of subjects: 0
Study 31685476 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel and DSM265 combination treatment
Number of subjects: 0
Study 31685491 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at doses 15 to 200 μg/kg every 3 weeks
Number of subjects: 88
Study 31685491 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at doses ≥120 μg/kg
Number of subjects: 88
Study 31685491 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (all doses)
Number of subjects: 88
Study 31685491 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at doses ≥150 μg/kg
Number of subjects: 88
Study 31685491 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 88
Study 31685499 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium consumption in quintiles Q2-Q5
Number of subjects: 6473
Study 31685499 — intervention group
Group type: COMPARATOR
Intervention: Total magnesium intake
Number of subjects: 6473
Study 31685501 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led continuity model of care
Number of subjects: 200
Study 31685501 — intervention group
Group type: COMPARATOR
Intervention: Regular maternity care
Number of subjects: 200
Study 31685513 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine intervention aimed at improving physical activity (PA)
Number of subjects: 35
Study 31685513 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn accelerometers (Axivity AX3)
Number of subjects: 35
Study 31685527 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpyloric feeding
Number of subjects: 15
Study 31685527 — intervention group
Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 15
Study 31685558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (poly(ADP-ribose) polymerase inhibitor) as monotherapy
Number of subjects: 79
Study 31685586 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-menthol cigarettes for 2 weeks
Number of subjects: 29
Study 31686036 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (neoadjuvant treatment)
Number of subjects: 0
Study 31686289 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioners (GPs) involvement in decision-making process
Number of subjects: 109
Study 31686289 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with families post-decision
Number of subjects: 109
Study 31686289 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of GPs on their involvement
Number of subjects: 109
Study 31686289 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for involvement in end of life decisions
Number of subjects: 109
Study 31686289 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of end of life management in ED
Number of subjects: 109
Study 31686573 — intervention group
Group type: EXPERIMENTAL
Intervention: Supera Interwoven Nitinol Stents
Number of subjects: 0
Study 31686573 — intervention group
Group type: COMPARATOR
Intervention: Bare Nitinol Stents
Number of subjects: 0
Study 31687050 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 (Gal-3)
Number of subjects: 117
Study 31687050 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ST2 (sST2)
Number of subjects: 117
Study 31687050 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters
Number of subjects: 117
Study 31687203 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of Ranibizumab
Number of subjects: 0
Study 31687203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 loading doses of Ranibizumab
Number of subjects: 0
Study 31687203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Re Nata regimen using Ranibizumab
Number of subjects: 0
Study 31687205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day)
Number of subjects: 60
Study 31687205 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg/day)
Number of subjects: 60
Study 31687205 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 60
Study 31687922 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous CT-guided irreversible electroporation (IRE)
Number of subjects: 0
Study 31688003 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical device for blood pressure estimation (Aktiia OBPM algorithms)
Number of subjects: 31
Study 31688003 — intervention group
Group type: COMPARATOR
Intervention: Radial artery catheterization (reference method)
Number of subjects: 31
Study 31688330 — intervention group
Group type: EXPERIMENTAL
Intervention: RER calculated at the end of surgery
Number of subjects: 110
Study 31688340 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face contact in the transplant clinic
Number of subjects: 60
Study 31688340 — intervention group
Group type: EXPERIMENTAL
Intervention: Online transplant newsletter
Number of subjects: 60
Study 31688340 — intervention group
Group type: COMPARATOR
Intervention: Facebook and university website
Number of subjects: 60
Study 31688526 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic sacrocolpopexy using very lightweight polypropylene Y-mesh
Number of subjects: 253
Study 31688526 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent POP repair (5 native tissue anterior repairs and 5 native tissue posterior repairs)
Number of subjects: 253
Study 31688526 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a pessary for recurrent anterior POP
Number of subjects: 253
Study 31688526 — intervention group
Group type: EXPERIMENTAL
Intervention: No further prolapse treatment
Number of subjects: 253
Study 31688824 — intervention group
Group type: EXPERIMENTAL
Intervention: REPLETED (IVCD ≥ 10 mm)
Number of subjects: 144
Study 31688824 — intervention group
Group type: COMPARATOR
Intervention: NONREPLETED (IVCD < 10 mm)
Number of subjects: 144
Study 31688824 — intervention group
Group type: EXPERIMENTAL
Intervention: IVCDMIN
Number of subjects: 144
Study 31688824 — intervention group
Group type: EXPERIMENTAL
Intervention: IVCCI
Number of subjects: 144
Study 31688824 — intervention group
Group type: EXPERIMENTAL
Intervention: IJVDMIN
Number of subjects: 144
Study 31688824 — intervention group
Group type: EXPERIMENTAL
Intervention: IJVCI
Number of subjects: 144
Study 31689009 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Optical Scanning (3DO)
Number of subjects: 181
Study 31689009 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy x-ray absorptiometry
Number of subjects: 181
Study 31689155 — intervention group
Group type: EXPERIMENTAL
Intervention: DSTP3086S (2.4 mg/kg once every 3 weeks)
Number of subjects: 84
Study 31689155 — intervention group
Group type: EXPERIMENTAL
Intervention: DSTP3086S (doses > 2 mg/kg once every 3 weeks)
Number of subjects: 84
Study 31689155 — intervention group
Group type: COMPARATOR
Intervention: DSTP3086S (weekly dosing)
Number of subjects: 84
Study 31689242 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party EBV-specific cytotoxic T-lymphocytes (EBV-CTLs)
Number of subjects: 46
Study 31689242 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) from a different donor (switch therapy)
Number of subjects: 46
Study 31689608 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHEAR system
Number of subjects: 10
Study 31689608 — intervention group
Group type: COMPARATOR
Intervention: BCHA on a softband
Number of subjects: 10
Study 31689797 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 2
Study 31689797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metallic stents
Number of subjects: 2
Study 31689809 — intervention group
Group type: EXPERIMENTAL
Intervention: MESA questionnaire (translated and culturally adapted version)
Number of subjects: 0
Study 31689809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical extended assessment, 3-day voiding diary, International Consultation on Incontinence Questionnaire Short Form
Number of subjects: 0
Study 31689874 — intervention group
Group type: EXPERIMENTAL
Intervention: VisionSense VS3 NIRFI device for SLN identification
Number of subjects: 93
Study 31689874 — intervention group
Group type: COMPARATOR
Intervention: Lymphoscintigraphy (gold standard)
Number of subjects: 93
Study 31690104 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 8530
Study 31690104 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 8530
Study 31690104 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR and SAVR
Number of subjects: 8530
Study 31690284 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5% plus tropicamide 0.5%
Number of subjects: 60
Study 31690286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 100% oxygen at 2 atm absolute (ATA) for 90 minutes, 20 sessions for 5 days per week, followed by a second cycle of 20 sessions after 1 week of suspension.
Number of subjects: 12
Study 31690286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 12
Study 31690524 — intervention group
Group type: EXPERIMENTAL
Intervention: Treovance stent graft (for FNA patients)
Number of subjects: 200
Study 31690524 — intervention group
Group type: EXPERIMENTAL
Intervention: Treovance stent graft (for HNA patients)
Number of subjects: 200
Study 31690524 — intervention group
Group type: EXPERIMENTAL
Intervention: Treovance stent graft (for both groups)
Number of subjects: 200
Study 31690590 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe early childhood caries (ECC)
Number of subjects: 44
Study 31690590 — intervention group
Group type: COMPARATOR
Intervention: Caries-free children (control)
Number of subjects: 44
Study 31690644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic examination in group Y (aged under 40 years)
Number of subjects: 40
Study 31690644 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic examination in group O (aged over 60 years)
Number of subjects: 40
Study 31690644 — intervention group
Group type: EXPERIMENTAL
Intervention: Position (lateral and sitting)
Number of subjects: 40
Study 31690644 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal level (L3/4, L4/5, L5/S1)
Number of subjects: 40
Study 31690644 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterality (right and left paramedian sagittal oblique view)
Number of subjects: 40
Study 31690685 — intervention group
Group type: COMPARATOR
Intervention: Fewest comorbidities class (reference group)
Number of subjects: 0
Study 31690697 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-FGFR3 antibodies positive patients (65 out of 426)
Number of subjects: 426
Study 31690697 — intervention group
Group type: COMPARATOR
Intervention: Anti-FGFR3 antibodies negative patients (361 out of 426)
Number of subjects: 426
Study 31690932 — intervention group
Group type: COMPARATOR
Intervention: Early stage NAFLD
Number of subjects: 49
Study 31690932 — intervention group
Group type: COMPARATOR
Intervention: NASH
Number of subjects: 49
Study 31690932 — intervention group
Group type: COMPARATOR
Intervention: NAFLD patients with liver fibrosis
Number of subjects: 49
Study 31691133 — intervention group
Group type: COMPARATOR
Intervention: Low-dose formulation
Number of subjects: 25
Study 31691133 — intervention group
Group type: COMPARATOR
Intervention: High-dose formulation
Number of subjects: 25
Study 31691133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 31691148 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep head-down position with pneumoperitoneum during laparoscopic radical prostatectomy (LRP)
Number of subjects: 0
Study 31691148 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31691892 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPCR assay for T790M mutation in plasma
Number of subjects: 62
Study 31691897 — intervention group
Group type: EXPERIMENTAL
Intervention: IKORUS UP probe (urethral photoplethysmography-derived perfusion device)
Number of subjects: 30
Study 31692269 — intervention group
Group type: EXPERIMENTAL
Intervention: GAHT with TDF/FTC
Number of subjects: 16
Study 31692269 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC
Number of subjects: 16
Study 31692269 — intervention group
Group type: EXPERIMENTAL
Intervention: On demand (2 + 1 + 1) PrEP regimen with GAHT
Number of subjects: 16
Study 31693319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 89
Study 31693319 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency current (RFC)
Number of subjects: 89
Study 31693389 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback via electropalatography (EPG)
Number of subjects: 2
Study 31693389 — intervention group
Group type: COMPARATOR
Intervention: Sound Production Treatment (SPT)
Number of subjects: 2
Study 31693535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 3011
Study 31693535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol as monotherapy in de novo patients
Number of subjects: 3011
Study 31693535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol as add-on therapy to existing antihypertensives
Number of subjects: 3011
Study 31693621 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FAZA PET/CT imaging
Number of subjects: 1
Study 31694553 — intervention group
Group type: EXPERIMENTAL
Intervention: RARC
Number of subjects: 47
Study 31694553 — intervention group
Group type: COMPARATOR
Intervention: Control (open abdominal surgery in horizontal positioning)
Number of subjects: 47
Study 31694664 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntarily admitted patients
Number of subjects: 202
Study 31694664 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntarily admitted patients
Number of subjects: 202
Study 31694664 — intervention group
Group type: COMPARATOR
Intervention: Both groups (involuntarily and voluntarily admitted)
Number of subjects: 202
Study 31694664 — intervention group
Group type: COMPARATOR
Intervention: Stage of readiness to change at admission
Number of subjects: 202
Study 31694664 — intervention group
Group type: COMPARATOR
Intervention: SUD severity at baseline
Number of subjects: 202
Study 31694844 — intervention group
Group type: EXPERIMENTAL
Intervention: Few-Foods Diet (FFD)
Number of subjects: 100
Study 31694860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns of insulin pump users
Number of subjects: 0
Study 31694860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns of multiple daily injection users
Number of subjects: 0
Study 31694954 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapies and gene therapies
Number of subjects: 39600000
Study 31694954 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine research, viral transcript editing, T-cell effector response targeting including checkpoint inhibitors, and gene editing
Number of subjects: 39600000
Study 31694954 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting HIV-1 tissue reservoirs
Number of subjects: 39600000
Study 31695074 — intervention group
Group type: COMPARATOR
Intervention: Controlled asthma
Number of subjects: 203
Study 31695074 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 203
Study 31695074 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially controlled asthma
Number of subjects: 203
Study 31695346 — intervention group
Group type: EXPERIMENTAL
Intervention: Low density lipoprotein (LDL)
Number of subjects: 105
Study 31695346 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 105
Study 31695347 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium group (patients with delirium)
Number of subjects: 760
Study 31695439 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use autoinjector (AI) for benralizumab 30 mg
Number of subjects: 121
Study 31695667 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study 31695667 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham stimulation)
Number of subjects: 0
Study 31697246 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based cardiac rehabilitation (2 supervised sessions and 58 home sessions, guided by telephone)
Number of subjects: 72
Study 31697246 — intervention group
Group type: COMPARATOR
Intervention: CenterRehab (traditional supervised cardiac rehabilitation, 24 supervised sessions and 36 home sessions)
Number of subjects: 72
Study 31697246 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based cardiac rehabilitation
Number of subjects: 72
Study 31697246 — intervention group
Group type: COMPARATOR
Intervention: CenterRehab
Number of subjects: 72
Study 31697308 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 monotherapy
Number of subjects: 292
Study 31697308 — intervention group
Group type: COMPARATOR
Intervention: BMS-986156 plus nivolumab
Number of subjects: 292
Study 31697308 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 with or without nivolumab
Number of subjects: 292
Study 31697383 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning risk score
Number of subjects: 75558
Study 31697383 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based risk score
Number of subjects: 75558
Study 31697383 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-group strategy
Number of subjects: 75558
Study 31697647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-stimulated IFN-γ response
Number of subjects: 178
Study 31697647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific IFN-γ response
Number of subjects: 178
Study 31697647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV ELISpot-positive infants
Number of subjects: 178
Study 31697647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV ELISpot-negative infants
Number of subjects: 178
Study 31697647 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV- signature
Number of subjects: 178
Study 31697647 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-gene signature
Number of subjects: 178
Study 31698104 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrations of IL-1β in endometrial secretion
Number of subjects: 120
Study 31698104 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrations of TNF-α in endometrial secretion
Number of subjects: 120
Study 31698328 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 1037
Study 31698334 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive
Number of subjects: 24
Study 31698334 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive with feedback
Number of subjects: 24
Study 31698334 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring
Number of subjects: 24
Study 31698337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence threshold of ≥100 steps/min
Number of subjects: 75
Study 31698454 — intervention group
Group type: EXPERIMENTAL
Intervention: Etranacogene dezaparvovec (2 × 10^13 genome copies/kg)
Number of subjects: 3
Study 31698933 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3828
Study 31698933 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 3828
Study 31698933 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 3828
Study 31698933 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3828
Study 31698986 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-ASPECTS and ischemic core volume assessment
Number of subjects: 0
Study 31699157 — intervention group
Group type: COMPARATOR
Intervention: Automated tablet audiometer
Number of subjects: 124
Study 31699157 — intervention group
Group type: COMPARATOR
Intervention: Tablet audiometer for monosyllabic word recognition testing
Number of subjects: 124
Study 31699157 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated tablet audiometric evaluation
Number of subjects: 124
Study 31699278 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with de novo heart failure at hospital presentation
Number of subjects: 10443